At TNI BioTech, Inc., our goal is to benefit patients with chronic and often life-threatening diseases through the activation and rebalancing of the body's immune system using our patented immunotherapy.
Our products, technologies, and patents are designed to harness the power of the immune system to improve the treatment of cancer and infections, such as HIV/AIDS and autoimmune diseases. We are currently developing active and adoptive forms of immunotherapies.
Our most advanced clinical programs involve immunotherapy with methionine-enkephalin (MENK) or low dose naltrexone, which both work by triggering opioid receptors on immune cells and lead to an activation and expansion of various cells in the immune system.
Methionine enkephalin was found to increase significantly the active T-cell rosettes from lymphoma patients. In sharp contrast, the leucine enkephalin was observed to increase active rosettes only at a single low concentration. Neither enkephalin significantly altered the total T-cell rosettes. It is suggested that methionine enkephalin could have a significant influence in enhancing cell-mediated immunity and T-cell function, particularly in lymphoma patients